| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer | Chief Growth Officer
1 company
Freeman Kevin Lee is a Chief Commercial Officer at HCAT. Recent filings cover 0 purchases and 3 sales. Those positions are worth an estimated $653K at current prices.
Our model assigns Freeman Kevin Lee a middling insider score of 64/100, based on 3 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +54.7%.
Freeman Kevin Lee's largest disclosed position is in HCAT as Chief Commercial Officer, worth about $653K. The recent filings there lean toward selling, a net 22,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | HCAT Health Catalyst, Inc. | Chief Commercial Officer | Sell | 7,500 | $8.94 | $67,073.25 | -3.1% | -49.0% | -69.4% | |
| Sep 3, 2024 | HCAT Health Catalyst, Inc. | Chief Commercial Officer | Sell | 7,500 | $7.22 | $54,174.00 | -2.8% | +24.4% | -55.3% | |
| Jun 11, 2024 | HCAT Health Catalyst, Inc. | Chief Commercial Officer | Sell | 7,500 | $6.53 | $49,008.00 | -2.7% | +14.4% | -39.4% |